Two delivery‑focused RNA plays signaled momentum in RNA therapeutics beyond the liver. City Therapeutics, led by RNAi veteran John Maraganore, is developing cleavage‑inducing tiny guide RNAs (cityRNAs) intended to broaden tissue reach for RNAi modalities into CNS, eye, muscle and lung. Separately, BreezeBio closed a $60 million Series B to advance its polymer nanoparticle delivery platform and a tolerance‑inducing mRNA program for diabetes toward the clinic. Both moves underscore investor focus on next‑generation RNA delivery chemistries and formulations to unlock new indications.